Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Ruben J Boado
 -- 2105 2022-07-27 17:00:48 |
2 update references and layout
Rita Xu
 -15 word(s) 2090 2022-07-28 03:16:56 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Boado, R.J. Genetic Engineering of IgG Fusion Proteins. Encyclopedia. Available online: https://encyclopedia.pub/entry/25590 (accessed on 26 December 2024).
Boado RJ. Genetic Engineering of IgG Fusion Proteins. Encyclopedia. Available at: https://encyclopedia.pub/entry/25590. Accessed December 26, 2024.
Boado, Ruben J.. "Genetic Engineering of IgG Fusion Proteins" Encyclopedia, https://encyclopedia.pub/entry/25590 (accessed December 26, 2024).
Boado, R.J. (2022, July 27). Genetic Engineering of IgG Fusion Proteins. In Encyclopedia. https://encyclopedia.pub/entry/25590
Boado, Ruben J.. "Genetic Engineering of IgG Fusion Proteins." Encyclopedia. Web. 27 July, 2022.
Genetic Engineering of IgG Fusion Proteins
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics14071476

The treatment of neurological disorders with large-molecule biotherapeutics requires that the therapeutic drug be transported across the blood–brain barrier (BBB). Recombinant biotherapeutics, such as neurotrophins, enzymes, decoy receptors, and monoclonal antibodies (MAb), do not cross the BBB. These biotherapeutics can be re-engineered as brain-penetrating bifunctional IgG fusion proteins. These recombinant proteins comprise two domains, the transport domain and the therapeutic domain, respectively. The transport domain is an MAb that acts as a molecular Trojan horse by targeting a BBB-specific endogenous receptor that induces receptor-mediated transcytosis into the brain, such as the human insulin receptor (HIR) or the transferrin receptor (TfR). 

blood–brain barrier protein-based therapy monoclonal antibody

1. Introduction

The hematoencephalic or blood–brain barrier (BBB) is the anatomical and molecular barrier that separates in vivo the brain from the blood. This barrier evolved to prevent the transport to the brain of peripheral neurotransmitters, cytokines, and microorganisms, which may produce deleterious, if not lethal, effects in the central nervous system (CNS). The characteristics of this barrier have been extensively reviewed, and it is basically only permeable to lipophilic molecules of <400 Da [1][2][3][4]. Thus, histamine, a small polar molecule of 110 Da does not cross the BBB [2]. Hydrophobic nutrients of low molecular weight gain access to the brain through the BBB via facilitated transporters, as in the case of GLUT1 for glucose and LAT1 for large neutral amino acids [5][6]. Proteins, in general, do not cross the BBB; however, there are a few exceptions where proteins produced in peripheral organs gain access to the brain via receptor-mediated transcytosis, as in the case of insulin, transferrin, leptin, and insulin-like growth factor [7][8][9][10]. Targeting these BBB endogenous transporters with monoclonal antibodies gained attention in the early 1990s, and an in vivo demonstration of the efficacy of a brain-penetrating construct was published using vasopressin intestinal peptide (VIP) conjugated to the OX26 monoclonal antibody to the rat transferrin receptor using the avidin–biotin technology [11]. The administration of the OX26-avidin-biotinylated-VIP produced a marked increase in the brain blood flow. On the contrary, the biotinylated-VIP had no effect in the brain, as it does not cross the BBB [11]. The construction and efficacy of chemical conjugates targeting either the transferrin or the insulin receptor in rodents and non-human primates have been reported [12][13][14][15].
With the cloning of monoclonal antibodies to the mouse transferrin (TfRMAb) and human insulin (HIRMAb) BBB receptors, respectively [16][17], the engineering of bifunctional IgG fusion proteins was possible [18][19][20]. These fusion proteins comprise a transport domain, i.e., TfRMAb or HIRMAb, and a therapeutic domain fused to the C-terminus of either the heavy or light chain of the transporting MAb. Thus, any potential protein therapeutic can be transported through the BBB into the brain in the form of a fusion protein targeting a BBB-receptor-mediated transport (Figure 1). In this schematic representation, a protein therapeutic in fused to the C-terminus of the transporting MAb, which binds to a BBB receptor, inducing the transport of the fusion protein through the BBB. The binding of the MAb fusion protein to its BBB receptor does interfere with the binding of its endogenous ligand, so both the ligand and the MAb fusion are transported through the BBB and released into the brain interstitial fluid. Depending on the characteristics of the therapeutic domain, the fusion protein can (i) target a receptor on the surface of brain cells, as in the case of neurotrophic factors; (ii) bind and inactivate a target molecule, as in the case of decoy receptors and bispecific MAbs; and (iii) be internalized in brain cells via receptor-mediated endocytosis through the same transport systems used to cross the BBB, as in the case of enzymes for the treatment of lysosomal storage disorders (LSD) and/or bispecific MAbs. A detailed mathematical model of receptor-mediated transport across the BBB was recently published [21]. A generation of IgG fusion proteins targeting both the human and mouse BBB transport systems has been engineered (Table 1 and Table 2).
Pharmaceutics 14 01476 g001
Figure 1. Receptor-mediated transport of IgG fusion proteins across the BBB. Biologicals (red circle) do not cross the BBB and stay in circulation following IV administration, as in the case of enzymes, MAbs, decoy receptors, and/or neurotrophic factors. These potential therapeutic agents for the CNS can be re-engineered as fusion proteins with an MAb targeting a BBB receptor that induces receptor-mediated transcytosis (R1), such as the human BBB insulin receptor (HIR) or the transferrin receptor (TfR). The transport domain of the IgG fusion protein targets the BBB R1 endogenous receptor to gain access to the brain. The transport MAb binds to an exofacial epitope of the receptor without interfering with the normal transport of its endogenous ligand (green rectangle) to gain access to the brain. Depending on the therapeutic domain of the IgG fusion protein, it can (i) bind to its ligand in the brain interstitial compartment, as in the case of bispecific MAbs or decoy receptors; (ii) target a brain cell membrane receptor (R2), such as neurotrophic factors; or (iii) be endocytosed via the same targeted R1 receptor in brain cells as lysosomal enzymes to produce physiological and/or neuropharmacological effect.
Table 1. Brain-penetrating human IgG fusion proteins.
IgG Fusion Protein 1 Therapeutic Domain Indication Reference
HIRMAb-IDUA (valanafusp alpha) Iduronidase (IDUA) Hurler syndrome (MPS I) [22]
HIRMAb-IDS Iduronate-2-sulfatase (IDS) Hunter syndrome (MPS II) [23]
TfRMAb-IDS (pabinafusp alfa) Iduronate-2-sulfatase (IDS) Hunter syndrome (MPS II) [24]
HIRMAb-ASA Arylsulfatase A (ASA) Metachromatic leukodystrophy * [25]
HIRMAb-SGSH Sulfamidase (SGSH) Sanfilippo A (MPSIIIA) * [26]
HIRMAb-NAGLU N-acetyl-alpha-D-glucosaminidase (NAGLU) Sanfilippo B (MPSIIIB) * [27]
HIRMAb-ASM Acid shingomyelinase (ASM) Niemann–Pick A/B * [28]
HIRMAb-HEXA Hexoaminidase A (HEXA) Tay–Sachs * [28]
HIRMAb-PPT1 Palmitoyl-protein thioesterase (PPT1) Batten Type 1 * [28]
HIRMAb-GLB1 β-galactosidase (GLB1) GM1-gangliosidosis * [28]
HIRMAb-Aβ bispecific antibody Anti-Aβ amyloid single-chain Fv antibody (scFv) Alzheimer’s * [29]
HIRMAb-TNFR Tumor necrosis factor decoy receptor (TNFR) Parkinson’s, ALS, Alzheimer’s, and/or stroke * [30]
HIRMAb-EPO Erythropoietin (EPO) Parkinson’s, Alzheimer’s, and/or Friedreich ataxia * [31]
HIRMAb-GDNF Glial-cell-derived neurotrophic factor (GDNF)) Parkinson’s, stroke, and/or drug/EtOH addiction * [32]
HIRMAb-BDNF Brain-derived neurotrophic factor (BDNF) Stroke, neural repair * [33]
HIRMAb-Avidin Any mono-biotinylated therapeutic Various [34]
1 The transport domain of these human fusion proteins is a monoclonal antibody directed to the human BBB insulin receptor (HIRMAb) or the transferrin receptor (TfRMAb). The therapeutic domain of the fusion protein and its application are listed for the corresponding IgG fusion protein. * Indication has a primary CNS disease burden.
Table 2. Brain-penetrating mouse IgG fusion proteins.
IgG Fusion Protein 1 Therapeutic Domain Indication Reference
TfRMAb-IDUA Iduronidase (IDUA) Hurler syndrome (MPS I) [35]
TfRMAb-IDS Iduronate-2-sulfatase (IDS) Hunter syndrome (MPS II) [36]
TfRMAb-SGSH Sulfamidase (SGSH) Sanfilippo A (MPSIIIA) * [37]
TfRMAb-Aβ bispecific antibody Anti-Aβ amyloid single-chain Fv antibody (scFv) Alzheimer’s * [38]
TfRMAb-TNFR Tumor necrosis factor decoy receptor (TNFR) Parkinson’s, Alzheimer’s, and/or stroke * [39]
TfRMAb-EPO Erythropoietin (EPO) Parkinson’s, Alzheimer’s, and/or stroke * [40]
TfRMAb-GDNF Glial-cell-derived neurotrophic factor (GDNF)) Parkinson’s, and/or stroke * [41]
TfRMAb-Avidin Any mono-biotinylated therapeutic Various [42]

1 The transport domain of these mouse fusion proteins is a monoclonal antibody directed to the mouse BBB-transferrin receptor (TfRMAb). The therapeutic domain of the fusion protein and its experimental application are listed for the corresponding IgG fusion protein. * Indication has a primary CNS disease burden.

2. Genetic Engineering of IgG Fusion Proteins

The genetic engineering of IgG fusion proteins has been performed using either individual expression vectors for light- and heavy-chain expression genes or tandem vectors carrying both light- and heavy-chain expression genes [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]. The cDNA corresponding to the mature therapeutic domain (without the signal peptide) is ligated into the C-terminus of the appropriate expression gene via designed restriction endonuclease sites, which provides a short linker composed of 2–4 serine residues. The therapeutic gene can be inserted in either the heavy or light chain of the transport MAb, and a few examples are shown in Figure 2. In particular cases, the short linker approach produces suboptimal levels of enzyme activity and/or production, which may be restored by the introduction of a long 31-amino-acid linker corresponding to the IgG3 hinge region [27][28]. The engineering of IgG fusion proteins may be performed by fusing the therapeutic domain on the N-terminus of the transport MAb, i.e., the heavy chain of the MAb. However, it was demonstrated using a glucuronidase (GUSB) fusion protein that this construct had a marked reduction in the affinity for the target receptor, to levels that would abolish its transport through the BBB [43]. For studies in rodents, the engineering of IgG fusion proteins has been performed targeting the mouse or rat transferrin receptor [17][19][20][44]. For studies in humans and non-human primates, the IgG fusion proteins were initially produced with an MAbs directed to the human insulin receptor, and lately the MAbs have been directed to the human transferrin receptor as well [16][24]. The anti-human insulin receptor MAb cross-reacts with the BBB insulin receptor of old-world primates, such as the rhesus monkey [45]. Targeting the rodent transferrin receptor or the human insulin or transferrin receptors at the BBB resulted in a comparable brain uptake of 1–3% of the injected dose. This relates to the abundance of these receptors at the BBB, which is comparable in humans [46]. However, the abundance of the mouse BBB transferrin receptor is approximately 7-fold higher than that of the mouse BBB insulin receptor [46][47]. Therefore, targeting the mouse BBB insulin receptor would produce lower levels of brain uptake. The manufacturing of IgG fusion proteins presents advantages compared to chemical conjugation, including simplified downstream purification due to protein-A capture [48]. IgG fusion proteins were engineered targeting both transferrin and insulin BBB receptors with high affinities in the low nM range (Table 1 and Table 2). The extensive number of peer-reviewed publications discussed below validated the high-affinity approach for the transport across the BBB, targeting either the insulin or the transferrin receptor.
Pharmaceutics 14 01476 g002
Figure 2. Genetic engineering of IgG fusion proteins. The therapeutic domain of the IgG bifunctional fusion protein can be fused to the C-terminus of either the heavy or light chain of the transport monoclonal antibody (MAb), in this case targeting the BBB human insulin receptor (HIR). The indication for these IgG fusion proteins is: HIRMAb-PPT1, Batten disease type 1; HIRMAb-GLB1, GM1-gangliosidosis; HIRMAb-HEXA, Tay–Sachs disease; and HIRMAb-ASM, Niemann–Pick disease types A and B. From reference [28].
There are, however, few publications postulating that a low-affinity monovalent MAb directed to the BBB TfR transport system may result in improved brain uptake [49][50]. This is based on the hypothesis that bivalent TfRMAbs cause TfR clustering and selective triage of the antibody-TfR complex to the lysosome and degradation of TfR on the cell membrane, whereas this is avoided with monovalent TfRMAbs [49][50]. However, this was based on tissue culture experiments with TfRMAb-avidin fusion proteins, which are known to form tetrameric structures from the association of avidin monomers [51][52]. No toxic effects of other high-affinity TfRMAb fusion proteins were reported in in vitro or in vivo studies. Chronic treatment with intravenous (IV) 2 mg/kg BW TfRMAb-GDNF twice weekly for 12 weeks produced no downregulation of the BBB TfR, as the terminal pharmacokinetics and brain uptake were comparable to those obtained prior to the chronic treatment [53]. Moreover, no evidence of BBB TfR downregulation was reported in a chronic study performed in the cynomolgus monkey with pabinafusp alfa, the high-affinity human TfRMAb-IDS fusion protein, with doses up to 30 mg/kg/week for 26 weeks [54]. Kinetics modeling of the receptor-mediated transport across the BBB showed that the optimal receptor-binding properties would be an MAb with a KD of 0.5–5 nM and an association rate constant (kon) of 105–106 M−1 s−1, which would produce a dissociation T1/2 of ~10–120 min [55]. Targeting MAbs, i.e., TfRMAb and/or HIRMAb, with these kinetic properties produced therapeutic brain delivery at a low injection dose of 1–3 mg/kg BW in the various CNS models discussed below, including clinical trials in LSD.
The brain uptake via a BBB receptor-mediated transport is a function of the antibody affinity for the receptor, the injection dose, and the plasma area under the curve (AUC), which may be affected by the therapeutic domain of the fusion protein, as in the case of LSD enzymes targeting peripheral M6P receptors. For example, the fusion of IDUA to the transport MAb reduces the brain AUC of the fusion protein compared to the MAb alone [56]. Kinetics modeling showed that the lower the affinity of the antibody for the TfR, the greater the ID required to maintain a given brain AUC [55]. For example, the brain AUC of a TfRMAb-IDUA fusion protein with a moderate affinity for the TfR, KD = 36 nM, would require an injected dose of 30 mg/kg BW to produce a brain AUC comparable to the one of a TfRMAb-IDUA fusion protein with high affinity (KD = 0.36–3.6 nM) at a 10-fold lower injected dose of 3 mg/kg BW [55]. A lower therapeutic dose is also preferred to reduce potential adverse effects, as in the case of IgG-neurotrophic factor fusion proteins [31][57].

References

  1. Pardridge, W.M.; Boado, R.J.; Black, K.L.; Cancilla, P.A. Blood-brain barrier and new approaches to brain drug delivery. West. J. Med. 1992, 156, 281–286.
  2. Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2, 3–14.
  3. Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37, 13–25.
  4. Pardridge, W.M. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. Drug Deliv. 2016, 13, 963–975.
  5. Boado, R.J.; Pardridge, W.M. Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5′-untranslated region. Mol. Cell. Neurosci. 1990, 1, 224–232.
  6. Boado, R.J.; Li, J.Y.; Nagaya, M.; Zhang, C.; Pardridge, W.M. Selective expression of the large neutral amino acid trans-porter at the blood-brain barrier. Proc. Natl. Acad. Sci. USA 1999, 96, 12079–12084.
  7. Pardridge, W.M.; Eisenberg, J.; Yang, Y. Human blood-brain barrier insulin receptor. J. Neurochem. 1985, 44, 1771–1778.
  8. Fishman, J.B.; Rubin, J.B.; Handrahan, J.V.; Connor, J.R.; Fine, R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 1987, 18, 299–304.
  9. Boado, R.J.; Golden, P.L.; Levin, N.; Pardridge, W. Up-Regulation of Blood-Brain Barrier Short-Form Leptin Receptor Gene Products in Rats Fed a High Fat Diet. J. Neurochem. 2002, 71, 1761–1764.
  10. Duffy, K.R.; Pardridge, W.M.; Rosenfeld, R.G. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988, 37, 136–140.
  11. Bickel, U.; Yoshikawa, T.; Landaw, E.M.; Faull, K.F.; Pardridge, W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA 1993, 90, 2618–2622.
  12. Kang, Y.S.; Bickel, U.; Pardridge, W.M. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab. Dispos. 1994, 22, 99–105.
  13. Wu, D.; Boado, R.J.; Pardridge, W.M. Pharmacokinetics and blood-brain barrier transport of -biotinylated phos-phorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 1996, 276, 206–211.
  14. Wu, D.; Yang, J.; Pardridge, W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Investig. 1997, 100, 1804–1812.
  15. Xia, C.-F.; Zhang, Y.; Zhang, Y.; Boado, R.J.; Pardridge, W.M. Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology. Pharm. Res. 2007, 24, 2309–2316.
  16. Coloma, M.J.; Lee, H.J.; Kurihara, A.; Landaw, E.M.; Boado, R.J.; Morrison, S.L.; Pardridge, W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 2000, 17, 266–274.
  17. Boado, R.J.; Zhang, Y.; Wang, Y.; Pardridge, W.M. Engineering and expression of a chimeric transferrin receptor mono-clonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 2009, 102, 1251–1258.
  18. Boado, R.J. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery. Drug News Perspect. 2008, 21, 489–503.
  19. Pardridge, W.M. Re-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan Horses. Bioconjug. Chem. 2008, 19, 1327–1338.
  20. Pardridge, W.M.; Boado, R.J. Reengineering Biopharmaceuticals for Targeted Delivery Across the Blood–Brain Barrier. Methods Enzymol. 2012, 503, 269–292.
  21. Pardridge, W.; Chou, T. Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. Pharmaceuticals 2021, 14, 535.
  22. Boado, R.J.; Zhang, Y.; Zhang, Y.; Xia, C.-F.; Wang, Y.; Pardridge, W.M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 99, 475–484.
  23. Lu, J.Z.; Boado, R.J.; Hui, E.K.; Zhou, Q.H.; Pardridge, W.M. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol. Bioeng. 2011, 108, 1954–1964.
  24. Sonoda, H.; Morimoto, H.; Yoden, E.; Koshimura, Y.; Kinoshita, M.; Golovina, G.; Takagi, H.; Yamamoto, R.; Minami, K.; Mizoguchi, A.; et al. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Mol. Ther. 2018, 26, 1366–1374.
  25. Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Sumbria, R.K.; Pardridge, W.M. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol. Bioeng. 2012, 110, 1456–1465.
  26. Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Pardridge, W.M. Insulin Receptor Antibody—Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells. Mol. Pharm. 2014, 11, 2928–2934.
  27. Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Lin, H.; Pardridge, W.M. Insulin Receptor Antibody−α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts. Mol. Pharm. 2016, 13, 1385–1392.
  28. Boado, R.J.; Lu, J.Z.; Hui, E.K.; Lin, H.; Pardridge, W.M. Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery. Sci. Rep. 2019, 9, 18632.
  29. Boado, R.J.; Zhang, Y.; Zhang, Y.; Xia, C.F.; Pardridge, W.M. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and Aβ fibril disaggregation. Bioconjug. Chem. 2007, 18, 447–455.
  30. Boado, R.J.; Hui, E.K.-W.; Lu, J.Z.; Zhou, Q.-H.; Pardridge, W.M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 2010, 146, 84–91.
  31. Boado, R.J.; Hui, E.K.-W.; Lu, J.Z.; Pardridge, W.M. Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse. J. Pharmacol. Exp. Ther. 2010, 333, 961–969.
  32. Boado, R.J.; Zhang, Y.; Zhang, Y.; Wang, Y.; Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood–brain barrier. Biotechnol. Bioeng. 2007, 100, 387–396.
  33. Boado, R.J.; Zhang, Y.; Zhang, Y.; Pardridge, W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 97, 1376–1386.
  34. Boado, R.J.; Zhang, Y.; Zhang, Y.; Xia, C.F.; Wang, Y.; Pardridge, W.M. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug. Chem. 2008, 19, 731–739.
  35. Boado, R.J.; Hui, E.K.-W.; Lu, J.Z.; Zhou, Q.-H.; Pardridge, W.M. Reversal of Lysosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein. Mol. Pharm. 2011, 8, 1342–1350.
  36. Zhou, Q.H.; Boado, R.J.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab. Dispos. 2012, 40, 329–335.
  37. Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Pardridge, W.M. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse–Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Mol. Pharm. 2017, 15, 602–608.
  38. Boado, R.J.; Zhou, Q.H.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. Pharmacokinetics and brain uptake of a genetically engi-neered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm. 2010, 7, 237–244.
  39. Zhou, Q.H.; Sumbria, R.; Hui, E.K.; Lu, J.Z.; Boado, R.J.; Pardridge, W.M. Neuroprotection with a brain-penetrating bio-logic tumor necrosis factor inhibitor. J. Pharmacol. Exp. Ther. 2011, 339, 618–623.
  40. Zhou, Q.-H.; Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Pardridge, W.M. Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood−Brain Barrier in the Mouse. Mol. Pharm. 2010, 7, 2148–2155.
  41. Zhou, Q.-H.; Boado, R.J.; Lu, J.Z.; Hui, E.K.-W.; Pardridge, W.M. Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse. Drug Metab. Dispos. 2010, 38, 566–572.
  42. Zhou, Q.H.; Lu, J.Z.; Hui, E.K.; Boado, R.J.; Pardridge, W.M. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug. Chem. 2011, 22, 611–618.
  43. Boado, R.J.; Pardridge, W.M. Genetic engineering of IgG-glucuronidase fusion proteins. J. Drug Target. 2010, 18, 205–211.
  44. Li, J.Y.; Sugimura, K.; Boado, R.J.; Lee, H.J.; Zhang, C.; Duebel, S.; Pardridge, W.M. Genetically engineered brain drug delivery vectors: Cloning, expression and in vivo application of an anti-transferrin receptor single chain anti-body-streptavidin fusion gene and protein. Protein Eng. 1999, 12, 787–796.
  45. Pardridge, W.M.; Kang, Y.-S.; Buciak, J.L.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 1995, 12, 807–816.
  46. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011, 117, 333–345.
  47. Hoshi, Y.; Uchida, Y.; Tachikawa, M.; Inoue, T.; Ohtsuki, S.; Terasaki, T. Quantitative atlas of blood-brain barrier trans-porters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 2013, 102, 3343–3355.
  48. Boado, R.J.; Hui, E.K.-W.; Lu, J.Z.; Pardridge, W.M. AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol. 2009, 144, 135–141.
  49. Ullman, J.C.; Arguello, A.; Getz, J.A.; Bhalla, A.; Mahon, C.S.; Wang, J.; Giese, T.; Bedard, C.; Kim, D.J.; Blumenfeld, J.R.; et al. Brain delivery and ac-tivity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci. Transl. Med. 2020, 12, 1163.
  50. Niewoehner, J.; Bohrmann, B.; Collin, L.; Urich, E.; Sade, H.; Maier, P.; Rueger, P.; Stracke, J.O.; Lau, W.; Tissot, A.C.; et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron 2014, 81, 49–60.
  51. Ng, P.P.; Dela Cruz, J.S.; Sorour, D.N.; Stinebaugh, J.M.; Shin, S.U.; Shin, D.S.; Morrison, S.L.; Penichet, M.L. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc. Natl. Acad. Sci. USA 2002, 99, 10706–10711.
  52. Ng, P.P.; Helguera, G.; Daniels, T.R.; Lomas, S.Z.; Rodriguez, J.A.; Schiller, G.; Bonavida, B.; Morrison, S.L.; Penichet, M.L. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 2006, 108, 2745–2754.
  53. Zhou, Q.-H.; Boado, R.J.; Hui, E.K.-W.; Lu, J.Z.; Pardridge, W.M. Chronic Dosing of Mice with a Transferrin Receptor Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein. Drug Metab. Dispos. 2011, 39, 1149–1154.
  54. Yamamoto, R.; Yoden, E.; Tanaka, N.; Kinoshita, M.; Imakiire, A.; Hirato, T.; Minami, K. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Mol. Genet. Metab. Rep. 2021, 27, 100758.
  55. Pardridge, W.M. Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor. Pharmaceuticals 2021, 15, 3.
  56. Boado, R.J.; Hui, E.K.; Lu, J.Z.; Pardridge, W.M. IgG-enzyme fusion protein: Pharmacokinetics and anti-drug antibody response in Rhesus monkeys. Bioconjug. Chem. 2013, 24, 97–104.
  57. Sun, J.; Boado, R.J.; Pardridge, W.M.; Sumbria, R.K. Plasma pharmacokinetics of high-affinity transferrin receptor anti-body-erythropoietin fusion protein is a function of effector attenuation in mice. Mol. Pharm. 2019, 16, 3534–3543.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ruben J. Boado
View Times: 358
Revisions: 2 times (View History)
Update Date: 02 Aug 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback